What Sanofi’s multiple sclerosis troubles could mean for the space

The company recently hit significant roadblocks with its BTK inhibitor, but there are plenty of fish in the sea for the drug ...
MedPage Today

Tolebrutinib Benefits Non-Relapsing Secondary Progressive Multiple Sclerosis

SAN DIEGO -- Investigational tolebrutinib slowed disability progression in people with non-relapsing secondary progressive multiple sclerosis (SPMS), the phase III HERCULES trial showed. The Bruton's ...
Healio

Tolebrutinib slows disability accumulation in secondary progressive multiple sclerosis

Please provide your email address to receive an email when new articles are posted on . Tolebrutinib was associated with a 31% reduced risk for 6-month confirmed disability progression vs. placebo.

AB Science receives Japanese patent protection for the use of masitinib in progressive forms of multiple sclerosis (MS) until 2041

PRESS RELEASEAB SCIENCE RECEIVES JAPANESE PATENT PROTECTION FOR THE USE OF MASITINIB IN PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS (MS) UNTIL ...
Monthly Prescribing Reference

Tolebrutinib Under Review for Non-Relapsing Secondary Progressive MS

The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application for tolebrutinib for the treatment of non-relapsing secondary progressive multiple sclerosis (nrSPMS).

Tiziana Life Sciences Announces the Peer-Reviewed Publication of Clinical Study Results for Intranasal Foralumab

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces the ...
Monthly Prescribing Reference

Tolebrutinib Looks Promising for Patients With Non-Relapsing Secondary Progressive MS

Findings showed the study met its primary endpoint demonstrating a reduction in disability accumulation with tolebrutinib compared with placebo. Tolebrutinib was found to delay disability progression ...
MedPage Today

Tolebrutinib Slows Disability in Non-Relapsing Secondary Progressive MS

Investigational tolebrutinib slowed disability progression in people with non-relapsing secondary progressive multiple sclerosis (SPMS), the phase III HERCULES trial showed. The Bruton's tyrosine ...
The American Journal of Managed Care

Multiple Sclerosis: Impact, Types, Pathophysiology, and Progression

Heidi Crayton, MD, and Maria Lopes, MD, discuss the impact of multiple sclerosis on patients, families, and caregivers, differentiate relapsing forms (relapsing-remitting and primary progressive) from ...
The American Journal of Managed Care

Tolebrutinib Delays Disability Progression in Nonrelapsing Secondary Progressive MS

The HERCULES study of tolebrutinib is the first and only to show reduced confirmed disability progression at 6 months in nonrelapsing secondary progressive multiple sclerosis (MS). The HERCULES ...
Pharmabiz

AB Science receives Japanese patent for use of masitinib in progressive forms of multiple sclerosis

AB Science receives Japanese patent for use of masitinib in progressive forms of multiple sclerosis: Paris Friday, January 23, 2026, 14:00 Hrs [IST] AB Science SA, a pharmaceutica ...